Gilead Sciences reported its strongest revenue growth in a decade, with Q3 revenues rising 16% excluding Veklury, driven mainly by a strong HIV franchise. However, the company faces challenges ahead as its key HIV drug Biktarvy will be subject to Medicare price controls in 2028, potentially cutting $1.5 billion in revenue that year. Other areas like oncology and immunology show weaker performance and limited near-term growth despite significant investment. The analyst maintains a Hold rating due to strong HIV sales but concerns about sustainable growth beyond this segment amid pipeline and pricing risks.
Gilead Sciences shares are trading at USD 172.48 on Pluang as of Oct 30, 2026 23:41 WIB, showing a 4.15% gain in the last day. The stock's market capitalization stands at $205.35 billion, reflecting strong investor interest. Despite the upbeat revenue growth reported, 19% of Pluang users are currently selling while 81% are buying, indicating mixed sentiment.
Gilead Sciences reported strong Q3 results with growth in HIV treatments and oncology drugs like Trodelvy. However, Medicare pricing changes will cut Biktarvy revenue by $1.5 billion annually starting in 2028, increasing Gilead's dependence on HIV pr...
Gilead Sciences reported strong Q3 results with revenue of $8.3 billion, beating analyst expectations and showing growth both quarterly and yearly. Sales of Trodelvy, a breast cancer drug, rose 41.7% year-over-year to $506 million. The company also a...
Assembly Biosciences has dosed the first two participants in a Phase 2 study of ABI-6250, an oral small-molecule drug for chronic hepatitis delta virus (HDV) infection. The study will enroll about 80 participants to evaluate safety, pharmacokinetics,...
Eli Lilly, Merck, and Gilead Sciences are set to report their Q3 2026 earnings on October 29, with Eli Lilly facing lowered EPS estimates amid strong GLP-1 drug demand, Merck dealing with tough comparisons for its cancer drug Keytruda, and Gilead man...
